Category: Health

Categories
Health

Brazil Reported One of many Highest Covid-19 Dying Tolls within the World

Brazil Reported One of the Highest Covid-19 Death Tolls in the World

The death toll of Covid-19 in Brazil has now exceeded 500,000, just behind the United States, which recorded 600,000 deaths last week, and India, where the death toll can range from 600,000 to 4.2 million.

Almost 18 million people have become infected so far, and the country is seeing an average of nearly 73,000 new cases and about 2,000 deaths per day, according to official figures. However, many experts believe the numbers underestimate the true scale of the country’s epidemic, as is the case in India.

Brazil’s President Jair Bolsonaro has been heavily criticized for dismissing the threat from the virus despite contracting himself last year. On Saturday, thousands of people protested his response to the pandemic, including his opposition to regulations on wearing masks and the slow adoption of vaccines, according to Reuters. It is believed that only 11 percent of residents are fully vaccinated.

A severe drought has also struck the country, the worst in at least 91 years, and experts say a terrible fire season could further complicate the country’s battle to fight the virus. The smoke could even make cases of Covid-19 worse by increasing inflammation in the lungs.

“It’s a dangerous situation,” said Dr. Aljerry Rêgo, professor and director of a Covid facility in the Amazon state of Amapá. “And, of course, the greatest risk is to further overwhelm the public health system, which is already precarious in the Amazon.”

In a recent testimony to a legislative committee, Brazil’s former Health Minister described Bolsonaros’ confusing belief that an anti-malaria drug would be effective against Covid-19, and a Pfizer executive said the company was offering millions of doses of its Covid-19 vaccine I went to Brazil last year – but received no response from the government for months.

Mr. Bolsonaro shrugged off the revelations. Last month, his government announced that Brazil would host the Copa America soccer tournament later this year after Argentina decided it would be irresponsible to do so while the virus continued to spread.

On Friday, officials reported that 82 people linked to the tournament had contracted Covid-19, according to The Associated Press. The Brazilian Ministry of Health said in a statement that 37 players and employees of the 10 tournament teams and 45 employees are infected.

Categories
Health

Gene testing agency 23andMe trades increased after Branson SPAC merger

Gene testing firm 23andMe trades higher after Branson SPAC merger

Anne Wojcicki, co-founder and CEO of 23andMe (right) celebrates with 23andMe employees after remotely ringing the NASDAQ opening bell at the headquarters of DNA technology company 23andMe in Sunnyvale, California, USA on June 17, 2021.

Peter DaSilva | Reuters

The newest trade on the exchange is “ME”.

23andMe, a personalized medicine and home genetic test kit company, went public on Thursday through a merger with a Richard Branson SPAC, VG Acquisition Corp..

23andMe stock rose 21% on the Nasdaq on its first day of trading as a publicly traded company.

Founded by Anne Wojcicki – the former wife of Google founder Sergey Brin who was an early investor in the company – 23andMe was founded 15 years ago. Together with Ancestry, it helped advance the idea that genetic testing is not just a medical field, but a big consumer business. His home test kits, which enabled people to find out their genetic profiles and ancestry by sending some saliva in the mail, ushered in a new era of personalized medicine, albeit not without controversy.

23andMe, a five-time CNBC Disruptor 50 company, had no straight or sure path to success as a publicly traded company.

It was reviewed by the FDA earlier in its history; Questions about consumer privacy continue to arise as genetic information is collected from millions of people; has run into financial difficulties in recent years when the market for personalized genetic testing seemed saturated; Skepticism about the basis of their gene-based risk analysis remains controversial; and as it delves deeper into drug development, a gap in its current customer base and underlying genetic data between a mostly European genetic profile and an underrepresentation of many minorities and ethnic groups.

“It will take time … to really make sure we get all communities to participate in the research,” Wojcicki said Thursday morning in an interview with CNBC’s TechCheck. “You can’t make discoveries in a population if those people aren’t part of it. We need the right customers and we have to present the product to them in the right way.”

Wojcicki says the company has big things ahead of it for both its consumer and drug discovery and development platforms. Approximately 80% of 23andMe’s 11 million members now choose to share their genetic information (anonymized) for drug development research.

“Our genetics represent all of life on this planet and we have the opportunity to understand what it means and, in doing so, it will improve your own life, but it will also contribute to all kinds of research discoveries,” said Wojcicki.

She says the controversy over the medical usefulness of the information won’t go away once it is put into the hands of consumers, and it ranges from critical, clinical information such as mutations in the gene that causes breast cancer, BRCA, to “more controversial” genetic ones Information on variants of Alzheimer’s disease. Some people at higher risk of blood clots choose to walk around more during flights based on their 23andMe reports.

However, she added that consumers have shown that they want this information to help them make decisions.

In the case of Alzheimer’s risk, she said, “This information … really affects how they live their lives … how they retire … plan to get older.”

Her own 10-year-old son used the company’s lactose intolerance analysis to diagnose his abdominal pain, and Wojcicki herself said, although she was reluctant to talk about her personal use of the product, as the daughter of a woman who suffered from breast cancer and who a higher risk of illness, the information influences their decision to drink that “leisure glass of wine”.

“Over the past 15 years we’ve built the infrastructure so we can take off to prove to consumers that we can get the information and understand it without a healthcare professional,” she said.

In her opinion, the key to the future is that consumers want to use the information not only to change their lives, but also to contribute to drug discovery.

23andMe has 40 programs ongoing on its drug discovery platform.

“We want them to have a truly personalized health experience and … benefit the human genome when all of this aggregated data is turned into therapeutic programs,” said Wojcicki. “When I think about the future of therapeutics, the next five years are really about moving these programs forward and getting them into the clinic.”

The company also recently launched a subscription product to bring more content and services to consumers who want to take extra steps after their genetic reports.

“We reach thousands of people who call the customer care team each week and want to know how this information can be used and applied to lead healthier longer lives,” she said.

The IPO market already set an annual record for the transaction volume of $ 171 billion in 2021, and only halfway through the year. Average first day trading profits on trades this year were over 40%. Although both the traditional IPO market and SPAC yields have cooled in recent months, the Renaissance IPO ETF and CNBC SPAC Index have been negative since the start of 2021, with a continuation of last year’s big gains since the start of the year. Meanwhile, concerns about SPAC deals have increased, and some high profile SPACs like Branson’s Virgin Galactic and electric vehicle maker Lordstown Motors have shown high levels of volatility.

Nonetheless, Branson and other investors plan to bring another space company, the satellite internet service Virgin Orbit, to the public via a SPAC in the coming weeks.

This history has been updated for the company’s closing price on the first day of trading on Thursday.

SIGN IN for our weekly original newsletter that goes beyond the list and offers a closer look at CNBC Disruptor 50’s companies and the founders who continue to innovate in all areas of the economy.

Categories
Health

Covid Lab-Leak Principle Renews “Achieve-of-Operate” Analysis Debate

Covid Lab-Leak Theory Renews "Gain-of-Function" Research Debate

In the United States, “there are no biosafety rules or regulations that have the force of law,” he said. “And this is in contrast to every other aspect of biomedical research.” There are enforceable rules, for example, for experiments with human subjects, vertebrate animals, radioactive materials and lasers, but none for research with disease-causing organisms.

Dr. Relman, who also supports the need for independent regulation, cautioned that legal restrictions, as opposed to guidelines or more flexible regulations, could also pose problems. “The law is cumbersome and slow,” he said. At one point in the evolution of laws relating to biological warfare, for example, Congress prohibited the possession of smallpox. But the rule’s language, Dr. Relman said, also seemed to ban possession of the vaccine because of its genetic similarity to the virus itself. “To try to fix it took forever,” he said.

The current H.H.S. policy also doesn’t offer much guidance about working with scientists in other countries. Some have different policies about gain-of-function research, while others have none at all.

Dr. Gronvall of Johns Hopkins argued that the U.S. government cannot dictate what scientists do in other parts of the world. “You have to embrace self-governance,” she said. “You’re not able to sit on everyone’s shoulder.”

Even if other countries fall short on gain-of-function research policies, Dr. Lipsitch said that shouldn’t stop the United States from developing better ones. As the world’s leader in biomedical research, the country could set an example. “The United States is sufficiently central,” Dr. Lipsitch said. “What we do really does matter.”

Ironically, the pandemic put deliberations over such issues on hold. But there’s no question the coronavirus will influence the shape of the debate. Jesse Bloom, a virologist at the Fred Hutchinson Cancer Research Center, said that before the pandemic, the idea of a new virus sweeping the world and causing millions of deaths felt hypothetically plausible. Now he has seen what such a virus can do.

“You have to think really carefully about any kind of research that could lead to that sort of mishap in the future,” Dr. Bloom said.

Categories
Health

Biden is on observe to fall in need of vaccinating 70% of American adults by the Fourth of July

Biden is on track to fall short of vaccinating 70% of American adults by the Fourth of July

President Joe Biden speaks in the Eisenhower Executive Office Building in Washington, D.C., U.S., on Wednesday, June 2, 2021.

Samuel Corum | Bloomberg | Getty Images

With less than three weeks to go until Independence Day, President Joe Biden’s latest vaccination goals are in jeopardy.

The country is not on pace to hit his two main targets outlined in early May: fully vaccinating 160 million adult Americans and administering at least one shot to 70% of adults across the U.S. by July 4, according to a CNBC analysis of Centers for Disease Control and Prevention data.

About 65% of adults are at least partially vaccinated as of Wednesday, CDC data shows. Roughly 13.6 million would have to receive their first shot over the next 18 days to get that figure to 70%, an average of about 756,000 new vaccinations each day. The U.S., however, is averaging 336,000 newly vaccinated adults per day over the past week.

If the U.S. maintains that latest seven-day average, 67% of adults will be at least partially vaccinated by that day.

When asked about the consequences of missing the 70% target at a news briefing last week, the White House’s chief medical advisor, Dr. Anthony Fauci, said the Fourth of July would not be the end of the country’s vaccination efforts as the risk of infection and illness remains for those who haven’t gotten a shot.

“If you don’t meet the precise goal and you fall short by a few percent, that doesn’t mean you stop in your effort to get people vaccinated,” Fauci said. “We want to reach 70% of the adult population by the Fourth of July. I believe we can, I hope we will, and if we don’t we’re going to continue to keep pushing.”

Fauci emphasized that people who don’t get vaccinated, are still at risk. “If you get vaccinated, you dramatically, dramatically diminish the risk of getting infected and almost eliminate the risk of serious disease,” he said.

Fauci, the nation’s top infectious disease expert, also stressed the importance of vaccination in preventing the delta variant, which was first identified in India and is rapidly emerging as the dominant strain in the U.K, from taking hold in the United States.

White House Covid czar Jeff Zients told reporters Thursday that the U.S. would cross the 70% mark and “continue across the summer months to push beyond 70%,” but did not specify whether he expects the country to reach that mark by the goal deadline.

Biden’s goal of 160 million fully vaccinated adults is also on track to fall short if the pace of shots does not pick up in the next few weeks. Nearly 142 million adults have completed a vaccination program, on pace to land at around 152 million on the Fourth of July assuming the current pace of daily reported vaccinations holds steady.

When Biden first announced the two goals on May 4, the country was on pace to hit both. But the vaccination rate has fallen in the weeks since, from a seven-day average of 2.2 million shots per day across all age groups on the day of the announcement to 1.2 million per day as of June 16, according to the CDC.

The White House has doubled down on recent efforts to boost the vaccination rate. Biden announced June as a “national month of action” in which his administration would mobilize national organizations, community- and faith-based partners, celebrities, athletes, and other influential groups to be part of the vaccination campaign. The White House also asked pharmacies to extend hours for the month of June and partnered with Uber and Lyft to offer free rides to vaccination sites.

States are also offering incentives ranging from free beer to $1 million lotteries to try to convince Americans to get jabbed. 

Though the nationwide rate is still about 5 percentage points away, 14 states and the District of Columbia have already crossed the 70% milestone. New York is the latest to get there, and Gov. Andrew Cuomo announced Tuesday that the state would lift most of its Covid restrictions as a result. 

Other states lag, with 22 of them below the 60% mark. That includes Mississippi, Alabama, Louisiana and Wyoming, which have each reached less than 50% of adult residents with one or more shots.

The U.S. has undoubtedly made progress in fighting Covid, and nationwide case counts are down to levels not seen since the start of the pandemic, which U.S. officials attribute to the country’s vaccination campaign. American life is closer to its pre-pandemic normal than at any point since last March now that the CDC’s lifted most of its mask recommendations and started to ease travel restrictions.

Even so, pockets of the U.S. with low vaccination rates are a risk for the country’s ability to control the pandemic, said Dr. Wafaa El-Sadr, a professor of epidemiology and medicine at Columbia University. 

“Once you have an unvaccinated population, that’s a vulnerable population likely to see surges in cases,” she said. Ongoing spread means the potential for new variants to emerge, with the possibility that one will be able to evade the protection offered by vaccines.

“It is valuable to have aspirations and very ambitious targets ahead of us and I think we should do our best to reach those targets,” El-Sadr said of Biden’s July 4 goals. “If we don’t reach them, it doesn’t mean that we accept it as a failure and stop doing what we’re doing. It means we redouble our efforts.”

Categories
Health

Covid Proved the C.D.C. Is Damaged. Can It Be Fastened?

Covid Proved the C.D.C. Is Broken. Can It Be Fixed?

MacCannell says he did everything he could to get the crisis under control: he and his team developed protocols to help public health labs launch new sequencing programs; developed plans to collaborate with commercial laboratories, which have a much larger overall capacity; and set up a consortium of scientists across the country to collaborate and pool resources. But those efforts are only stopgaps, he admits, and in any case, the approval and funding required to get started was delayed by many months. “There was a big gap between what we expected and what we actually saw,” says MacCannell. “Not just at the federal level, but at every step from there.”

Genomic surveillance is one of many shortcomings that plague the disease surveillance system that the CDC presides over. These deficiencies are invisible to anyone who does not work in the field, because at first glance the system makes sense. Public health emergencies identified at the local level are reported to state health officials and then passed on to the CDC as necessary, where officials analyze the information, issue guidelines, and coordinate federal action. There is a special system for the 120 or so “reportable diseases” – like Lyme disease and hepatitis – all of which agree are serious enough to warrant immediate action, and another for “syndromic surveillance,” according to the epidemiologist Search the emergency room in real time can search data on symptoms of concern. But under this broad structure there is often chaos.

As the coronavirus turned into a full blown pandemic, CDC scientists struggled to answer even basic questions about what the disease looked like or where or how it spread.

The system itself is profoundly disjointed and the technology behind it is less mature than many American households. State health departments are not meaningfully linked, nor are hospitals, clinics, laboratories and local health authorities. The CDC maintains more than 100 separate disease-specific computer systems (a by-product of the agency’s funding silos), and many of them cannot communicate with one another. Critical data is often passed from health facilities to health departments through a tortured process that can include handwritten notes, manual spreadsheets, fax machines, and mail. It is not uncommon for basic information such as race, ethnicity, age, or address to be missing from clinical reports. It’s also not uncommon for these reports to wane at the state or local level without ever getting to federal officials. Even the most serious diseases, which should be logged within 24 hours of their discovery and reported to the CDC in good time, are not necessarily systematically routed into this chain. “It depends on the jurisdiction,” Janet Hamilton, executive director of the State and Territorial Epidemiologists Council, recently told me. “Some regions have solid health departments and good reporting, while others don’t.”

Disease surveillance is also hampered by the uneven patchwork of surveillance programs across the country and the need to negotiate data sharing and other agreements with each state separately. Antibiotic resistance, respiratory infections and other pathogens are being tracked robustly in some areas and very poorly or not at all in others (for example, respiratory infections are monitored more closely in the Four Corners region than elsewhere), partly because the agency does not have the ability or authority to obtain all of the data it needs every community. Hanage compares the entire apparatus with a Rube Goldberg machine. “There is nothing central,” he says. “Random patchwork collaborations were initiated and transformed and are now having an overwhelming impact on our understanding of public health. Don’t let that criticize the people who did these things because the alternative couldn’t have been anything. But the result is something without a rational plan behind it. “

The loopholes make it difficult to track even known diseases and barely get a grip on new ones. During a recent romaine lettuce E. coli outbreak, officials were forced to make billion-dollar life or death decisions about which products to pull from which shelves in which regions of the country, based on data that included screenshots and text-messages to epidemiologists and health authorities. During the 2019 Vaping Injury (or Evali) outbreak, doctors faxed hundreds of pages of medical records directly to local health officials in some cases. Epidemiologists could hardly process the data in this format, let alone analyze it for clues. “There’s no pre-built process when something like a vaping injury or Zika or SARS-CoV-2 comes up,” says Hamilton. “There are 64 different public health jurisdictions in this country, and each will have their own ideas about what information should be collected and shared.”

In 2020, as the coronavirus went from a few isolated outbreaks to a full-blown pandemic, CDC scientists struggled to answer even basic questions about what the disease itself looked like or where or how it spread. “We were asked who is being hospitalized, who are the severe cases, what are the characteristics, and it was so frustrating,” Anne Schuchat, the agency’s deputy director, told a panel of colleagues last fall. “People went out to check graphs manually. I felt like the health sector has this data. It’s in their system. Can we work with them? ”The agency was unable to reliably track the number of tests or cases across the country. It also struggled to update hospital records, which include things like bed availability and ventilator supplies. The Trump administration hired a private contractor to collect this data on charges of political favoritism. And when multiple vaccines were eventually deployed, the agency was unable to monitor supplies or keep a close eye on waste.

Categories
Health

Singapore slows tempo of reopening as native circumstances stabilize

Singapore slows pace of reopening as local cases stabilize

A man wearing a protective face mask walks past an indoor waterfall at Jewel Changi Airport in Singapore.

Facebook Facebook logo Sign up on Facebook to connect with Roslan Rahman AFP | Getty Images

SINGAPORE – The Singapore government said Friday it would further relax Covid-related restrictions next week, albeit at a slower pace than previously announced, as local infections have not decreased significantly.

The government started easing some measures this week, including increasing restrictions on social gatherings and event attendees.

It said that as of Monday, “higher risk activities” such as eating in and indoor sports and exercise may be resumed in groups of two people – instead of the five people previously announced.

We remain concerned, especially if we do not have to reach a high level of vaccination yet,

Gan Kim Yong

Singapore’s Minister for Trade and Industry

Barring another super-spreader event or large cluster of infections, the government will allow these activities for groups of up to five people from mid-July.

“The number of cases in the community has stabilized somewhat, but it is not falling significantly and we see several unrelated cases every day,” said Gan Kim Yong, Singapore’s Minister of Commerce and Industry, co-chair of the Covid- Country Task Force.

“That’s why we remain concerned, especially if we don’t have to reach a high level of vaccination yet,” Gan told reporters at a briefing.

Singapore needs to be cautious in resuming activities that are viewed as more risky due to the more transmissible variant of the Delta, first discovered in India, Health Minister Ong Ye Kung said at the same meeting.

Ong, who is also co-chair of the Covid task force, said a gradual reopening will help “buy time to get more people vaccinated, so it is imperative now to step up vaccinations”.

Singapore has one of the fastest vaccinations in the Asia-Pacific region, but it is lagging behind many western countries. Around 2.7 million people – or about 49% of the population – had at least the first dose of the Covid vaccine by Tuesday, Ong said. Around 35% of the population are fully vaccinated, he added.

The country had largely controlled the spread of Covid until locally transmitted cases flared up in late April. Many of the recent cases have been caused by the Delta variant. The surge in cases forced the government to tighten social distancing measures twice last month.

The community’s daily reported cases dropped to single digits for most of the past week, but have remained above 10 cases a day since Sunday as a large cluster of infections emerged around a damp market in southern Singapore.

In total, the Southeast Asian country has reported 34 deaths and more than 62,300 confirmed cases since early 2020 as of Thursday, data from the Ministry of Health showed.

Categories
Health

How Emergent BioSolutions Earned Earnings However Delivered Disappointing Vaccine Returns

How Emergent BioSolutions Earned Profits But Delivered Disappointing Vaccine Returns

After placing the no-bid contract with Emergent, the Trump administration reverted to traditional contract rules and looked for competitive proposals for additional fillings and packaging, known in the industry as fill-finish work, the documents show. Ology Bioservices, based in Alachua, Fla., Agreed to provide essentially the same services as the Camden and Rockville Emergent plants for three quarters to nearly one third the cost, according to a contract-based calculation.

According to an agreement made in August, Ology would collect state fees of $ 6.83 per vial. By comparison, Emergent’s existing lines would cost between $ 9.03 and $ 18.40 per vial.

A health department spokeswoman said Ology is cheaper in part because it can fill more than 100,000 vials in a single batch, which is five times that of Emergent. This “lowers the price per bottle by spreading the fixed costs over more bottles,” she said in an email.

Even after the launch of Ology, the government continued its higher-cost agreement with Emergent to ensure “additional capacity is available when or when it is needed to fill vaccines or therapeutics,” she said. At the time of the deal, former and current federal officials said the government wanted to secure as much manufacturing capacity as possible before commercial companies buy it out.

Over the years, Emergent has grown by funding the expansion of its manufacturing facilities and the accumulation of product reserves.

In November 2019, the company announced that it would double its sales, including by expanding its contract manufacturing business. A senior vice president, Syed Husain, outlined a “game plan” that would “cross-sell additional services” to existing customers, including the federal government. Six months later, Emergent signed the contract that expanded its existing government contract to include work in its Camden and Rockville locations.

Dr. Robert Kadlec, a former Trump administration official who oversaw the agency that awarded Covid-19 contracts, had previously worked as a consultant for Emergent. Dr. Kadlec has said that he did not negotiate the emergent deal but approved it. Emergent said it negotiated the agreement with professional government officials.

Categories
Health

5 years earlier than vaccine can maintain line towards Covid variants

5 years before vaccine can hold line against Covid variants

Covid vaccinator, Petra Moinar, prepares syringes with the AstraZeneca vaccine before it is administered at Battersea Arts Centre on March 8, 2021 in London, England.

Chris J Ratcliffe | Getty Images News | Getty Images

LONDON — England’s top medical officer has warned that the coming winter will continue to be difficult for the country’s health system despite the country’s successful coronavirus vaccination program.

A further easing of lockdown restrictions in England was delayed this week due to a surge in cases of the delta variant first discovered in India. 

In a speech to the NHS Confederation Thursday, Chief Medical Officer Chris Whitty said the current wave of Covid infections due to the delta variant would likely be followed by another surge in the winter.

He said that Covid-19 “has not thrown its last surprise at us and there will be several more [variants] over the next period,” according to Sky News. He added that it would likely take five years before there are vaccines that could “hold the line” to a very large degree against a range of coronavirus variants.

And until then, he said that new vaccination programs and booster shots would be needed.

In the U.K., where the delta variant is now responsible for the bulk of new infections, cases have spiked among young people and the unvaccinated, leading to a rise in hospitalizations in those cohorts.

It’s hoped that Covid-19 vaccination programs can stop the spread of the delta variant and so the race is on to protect younger people who might not be fully vaccinated. 

Analysis from Public Health England released on Monday showed that two doses of the Pfizer-BioNTech or Oxford-AstraZeneca Covid-19 vaccines are highly effective against hospitalization from the delta variant.

But some vaccines are reported to be less effective against other strains. For example, British Health Secretary Matt Hancock said earlier this month that it has started commercial negotiations with AstraZeneca to secure a variant vaccine — which has been adapted to tackle the variant first discovered in South Africa.

Meanwhile, trials of booster shots are already underway in Britain and there are reports that the population will receive a third shot before winter this year. 

Over 42 million people have had a first dose of a vaccine in Britain — that’s about 80% of the adult population — and over 30 million people have had their second dose.

—CNBC’s Holly Ellyatt contributed to this article.

Categories
Health

Covid Survivors Scent Meals Otherwise

Covid Survivors Smell Foods Differently

“There are daily reports of recovery from long-distance drivers in terms of improvement in parosmia and fairly good sense of smell in patients,” said Professor Hopkins.

Ms. Viegut, 25, fears that she may not be able to detect a gas leak or fire. That’s a real risk, as shown by the experience of a family in Waco, Texas in January who didn’t realize their home was on fire. Almost all members had lost their sense of smell because of Covid; they escaped, but the house was destroyed.

Parosmia is one of several Covid-related problems related to smell and taste. Partial or complete loss of smell or anosmia is often the first symptom of the coronavirus. Loss of taste or ageusia can also be a symptom.

Prior to Covid, parosmia received relatively little attention, said Nancy E. Rawson, vice president and assistant director of the Monell Chemical Senses Center in Philadelphia, an internationally renowned nonprofit research group.

“We’d have a big conference and one of the doctors could have a case or two,” said Dr. Rawson.

In a French study from early 2005, the majority of the 56 cases examined were attributed to upper respiratory tract infections.

Today, scientists can point to more than 100 reasons for odor loss and distortion, including viruses, sinusitis, head trauma, chemotherapy, Parkinson’s disease, and Alzheimer’s disease, said Dr. Zara M. Patel, associate professor of ENT medicine at Stanford University and director of endoscopic skull base surgery.

Categories
Health

WHO says delta is turning into the dominant Covid variant globally

WHO says delta is becoming the dominant Covid variant globally

A joint government and NHS public information display will indicate that a Covid-19 variant concern has been identified locally and will provide guidance to residents on June 11, 2021 in Hounslow, UK.

Mark Kerrison | In pictures | Getty Images

Delta, the highly contagious variant of Covid-19 that was first identified in India, is becoming the dominant strain of the disease worldwide, the World Health Organization’s chief scientist said on Friday.

This is due to its “significantly increased transferability,” said Dr. Soumya Swaminathan, WHO senior scientist, during a press conference at the agency’s Geneva headquarters. Studies suggest Delta is about 60% more transmissible than Alpha, the variant first identified in the UK that was more contagious than the original strain that emerged from Wuhan, China in late 2019.

The situation worldwide “is so dynamic because of the variants circulating,” she added.

The variant has spread to more than 80 countries and continues to mutate as it spreads around the world, the WHO said on Wednesday. It now accounts for 10% of all new cases in the United States, up from 6% last week, according to the Centers for Disease Control and Prevention.

CDC director Dr. Rochelle Walensky urged Americans on Friday to get vaccinated against Covid, saying she expected Delta to become the dominant variant of coronavirus in the United States.

“As worrying as this Delta strain is about its hypertransmittance, our vaccines are working,” Walensky told ABC’s Good Morning America. If you get vaccinated, “you will be protected against this Delta variant,” she added.

In the UK, the Delta variety recently became the dominant variety there, surpassing Alpha, which was first discovered in the country last fall. The Delta variant now accounts for more than 60% of new cases in the UK

The WHO declared Delta a “questionable variant” last month. A variant can be described as “worrying” if, according to the health organization, it has been shown to be more contagious, more fatal, or more resistant to current vaccines and treatments.

WHO officials said Wednesday there are reports that the Delta variant also causes more severe symptoms, but that more research is needed to confirm these conclusions. Still, there is evidence that the Delta strain may cause different symptoms than other variants.

Swaminathan said Friday that scientists still need more data on the variant, including how it affects the effectiveness of Covid vaccines.

The German company CureVac earlier this week named variants as one of the reasons why its Covid vaccine was only 47% effective in a clinical study with 40,000 people.

An analysis published by Public Health England on Monday found that two doses of the Pfizer BioNTech or AstraZeneca Covid-19 vaccines are highly effective against hospitalizations from the Delta variant.

“How many become infected and how many of them are hospitalized and seriously ill?” said Swaminathan on Friday. “That is something that we are watching very closely.”

– CNBC’s Holly Ellyatt and Rich Mendez contributed to this report.